Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Ltd. (TEVA) is a global leader in generic medicines and biosimilars, delivering cost-effective healthcare solutions across 60+ countries. This dedicated news hub provides investors and professionals with verified updates on Teva’s strategic initiatives, regulatory milestones, and market developments.
Find official press releases, earnings reports, and analysis covering Teva’s core operations in generics manufacturing, innovative therapies, and active pharmaceutical ingredients (APIs). Our curated feed includes updates on FDA approvals, partnership announcements, patent developments, and sustainability initiatives impacting the pharmaceutical sector.
Bookmark this page to monitor Teva’s progress in biosimilar innovation, supply chain expansions, and responses to industry trends. All content is sourced from verified channels to support data-driven decisions in the evolving healthcare landscape.
Teva Pharmaceuticals and MedinCell announced the U.S. FDA has issued a Complete Response Letter for their New Drug Application for TV-46000 (risperidone extended-release injectable). This application aimed to treat schizophrenia but has been halted pending further review. Teva plans to collaborate with the FDA to address the feedback and continue product development. The application was based on two pivotal studies demonstrating the drug's safety and efficacy in managing schizophrenia symptoms.
Teva Pharmaceuticals, in collaboration with MedinCell, received a Complete Response Letter (CRL) from the FDA regarding the New Drug Application for TV-46000/mdc-IRM, an injectable treatment for schizophrenia. This letter indicates that the application cannot be approved in its current form. Teva aims to work with the FDA to address feedback and remains dedicated to developing this treatment. The application was based on Phase 3 data from two pivotal studies assessing the drug's efficacy and safety.
On April 5, 2022, National Caregiver Day in Canada, Teva Canada announced a partnership with People Before Patients to enhance healthcare delivery. They launched a series of five podcasts featuring healthcare leaders and initiated a national online survey to gather insights on improving Canadian healthcare. A live virtual event is scheduled for May 10, 2022, with keynote speaker Michael Landsberg. Teva Canada has also expanded its Caregiver-Friendly Pharmacy program, aimed at supporting the 8.1 million caregivers in Canada, amidst challenges from the pandemic.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its first quarter 2022 financial results on May 3, 2022, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Participants can join by dialing the following numbers: 1-877-870-9135 (US), 1-809-213-985 (Israel), or +44 (0) 2071 928338 (International) using passcode 8636304. A replay will be available shortly after the call. Teva is a global leader in generic and specialty medicines, offering over 3,500 products worldwide.
Teva Pharmaceuticals announced new data on AJOVY and AUSTEDO, showcasing their safety and efficacy at the American Academy of Neurology Annual Meeting from April 2-7, 2022. The research highlights include 11 abstracts on AJOVY for migraine treatment, focusing on its effectiveness across various patient demographics. Furthermore, AUSTEDO's long-term analyses for tardive dyskinesia were presented, revealing insights on treatment outcomes. Teva aims to enhance understanding of these therapies while supporting the healthcare community's knowledge.
Teva Pharmaceuticals has reached a settlement with Florida's Attorney General, resolving opioid-related claims. The agreement includes payments totaling $177 million over 15 years and provides generic Narcan (naloxone hydrochloride) valued at $84 million over 10 years. This resolution aims to assist those suffering from opioid addiction and does not imply any admission of liability by Teva. The company will maintain its defense in ongoing litigations in states without settlements.
Teva Pharmaceuticals has reached a settlement with Rhode Island's Attorney General concerning opioid-related claims, agreeing to pay $21 million over 13 years. Additionally, Teva will provide generic Narcan and Suboxone, valued at $78.5 million, over 10 years. This settlement is seen as a step towards addressing the opioid crisis and does not imply any admission of wrongdoing. Teva continues to pursue a national settlement, while stating that the agreement will help distribute life-saving treatments effectively in Rhode Island.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has launched the first generic version of Revlimid® (lenalidomide capsules) in the U.S., available in 5mg, 10mg, 15mg, and 25mg strengths. This launch provides vital treatment options for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. With an annual sales figure of $2.3 billion for Revlimid® as of December 2021, Teva's entry into this market strengthens its portfolio, which includes nearly 550 FDA-approved generic medicines, thus solidifying its status as a leader in the generics sector.
Teva Pharmaceuticals announces an update to the Summary of Product Characteristics for COPAXONE® (Glatiramer Acetate) in Europe, now approved for use in breastfeeding. This decision follows the COBRA study, which examined the effects on infants breastfed by mothers on GA treatment. The study involved 120 infants and found no adverse effects related to maternal GA exposure during breastfeeding. The update emphasizes the positive benefit/risk balance for MS patients wishing to breastfeed while receiving treatment.
